CDR-Life is developing powerful T-cell engagers (TCE) to eradicate hard-to-treat solid tumors. Our integrated antibody-based TCE platform unlocks access to a wide range of cancer antigens. We are leveraging this platform to advance a pipeline of potent and selective TCE therapeutics targeting intracellular and surface tumor antigens. With a team of proven drug development experts and backed by leading cross-Atlantic investors, we are working to empower patients’ own immune systems to eliminate tumors.
Externer Link zu CDR-Life Inc.
Tödistrasse 46
Horgen, Zurich 8810, CH
Honored to be recognized by Labiotech.eu as a Swiss biotech to watch! Curious about our innovative T-cell engagers? Discover how we're harnessing the immune system to fight cancer at www.cdr-life.com.
Take a look at these 18 Swiss biotech companies to keep an eye on.
Great news! CDR-Life Inc. expands its innovative cancer therapy portfolio with the addition of two highly tumor-targeted T cell engagers (TCE): - CDR813: A powerhouse T cell engager targeting PRAME in HLA-A*02:01 patients. PRAME is a clinically validated pan-cancer target expressed in a broad set of tumors including non-small cell lung cancer, endometrial cancer, melanoma and ovarian cancer but not in normal tissue. This bi-valent, bi-specific antibody shows unparalleled potency and precision. - CDR505: Breaking new ground with a T cell engager for KK-LC-1 in HLA-A01 patients. This expands treatment possibilities beyond the common HLA-A02 focus to benefit a large patient population with high unmet need. These additions strengthen CDR-Life's mission to develop targeted cancer therapies for broader patient populations. Read more: https://bit.ly/4bldGNA
We are thrilled to announce the initiation of enrollment for the Phase 1 trial of CDR404, our lead program in development as a precision immunotherapy for solid tumors. The study was published as an online presentation at #ASCO24 Based on the company’s unique M-gager® technology, CDR404 is a first-of-its-kind, antibody-based bivalent and bispecific MAGE-A4 T-cell engager (TCE) for the treatment of MAGE-A4 positive solid tumors. The Phase I study evaluating CDR404 is actively enrolling at sites in the U.S. and Europe. Read more: https://bit.ly/3UT8GcQ
CDR-Life has announced that Chief Medical Officer Swethajit Biswas will co-lead a seminar on translational insights into cell engager drugs at the 6th Annual Cell Engager Summit on May 21 in Boston. cdr-life.com/news/
Congrats to @Amgen on FDA approval of the second ever T cell Engager therapy in solid tumors. It is so exciting to see great progress being made in the T cell engager space. https://lnkd.in/eTBNVygY
Today, the U.S. FDA approved Amgen’s delta-like ligand 3-targeting Bispecific T-cell Engager (BiTE®) immunotherapy in adults with extensive-stage small cell lung cancer (ES-SCLC). Amgen is proud to deliver the first targeted immunotherapy to this patient population. 🔗 Press release: https://amgen.ly/3X35AWL
CDR-Life Inc. hat dies direkt geteilt
A pleasure to present results in our joint poster with Boehringer Ingelheim at ARVO. Together we are working to bring a much-needed treatment option to the millions of patients who are living with geographic atrophy disease. #ARVO2024
A pleasure to present results in our joint poster with Boehringer Ingelheim at ARVO. Together we are working to bring a much-needed treatment option to the millions of patients who are living with geographic atrophy disease. #ARVO2024
CDR-Life has announced the advancement of the Phase 1 study with BI 771716 for the treatment of #geographicatrophy: cdr-life.com/news/
CDR-Life has announced a presentation on its proprietary antibody-MHC technology for the development of highly specific T-cell engagers at the TCR-Based Therapies for Solid Tumors Summit: https://lnkd.in/eSmpkEZN
We recently announced the clearance of an IND application with the U.S. FDA for CDR404, our lead program in development as the first of its kind precision immunotherapy for solid tumors. CDR404 is an antibody-based, bivalent and bispecific MAGE-A4 T-cell engager (TCE) based on our unique M-gager® technology for targeting intracellular tumor antigens through the major histocompatibility complex (MHC). As we look ahead to initiating Ph 1 trial enrollment of CDR404 in the coming months, we are continuing to advance several additional programs leveraging our M-gager technology against promising intracellular cancer targets with the goal of improving patient lives. Stay tuned to learn what’s next from CDR-Life! Learn more here: https://lnkd.in/e2ME_tDq